Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
6,431 people get VVUS articles and Market Currents by email alert.
Get email alerts on VVUS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
GlobeNewswire (Thu, 7:00AM)
-
-
GlobeNewswire (Wed, 7:00AM)
-
GlobeNewswire (Tue, 7:00AM)
-
-
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 13, 2013)
-
-
-
-
GlobeNewswire (May 8, 2013)
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
VIVUS Management Discusses Q2 2012 Results - Earnings Call TranscriptTue, Aug 7, 2012 • 1 Comment
-
VIVUS CEO Discusses Q3 2010 Results - Earnings Call TranscriptMon, Nov 8, 2010
-
VIVUS Inc. Q2 2010 Earnings Call TranscriptMon, Aug 2, 2010
-
VIVUS, Inc. Q1 2010 Earnings Call TranscriptMon, May 3, 2010
-
VIVUS Inc. Q4 2008 Earnings Call TranscriptMon, Mar 9, 2009
-
VIVUS Inc. Q2 2008 Earnings Call TranscriptMon, Aug 4, 2008
-
VIVUS Inc. Q1 2008 Earnings Call TranscriptFri, May 30, 2008
-
VIVUS Inc. Q4 2007 Earnings Call TranscriptMon, Mar 24, 2008
-
GlobeNewswire (Thu, 7:00AM)
-
GlobeNewswire (Wed, 7:00AM)
-
GlobeNewswire (Tue, 7:00AM)
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 1, 2013)
-
GlobeNewswire (May 1, 2013)
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 26, 2013)
-
GlobeNewswire (Apr 22, 2013)
-
PR Newswire (Apr 16, 2013)
-
GlobeNewswire (Mar 26, 2013)
-
GlobeNewswire (Mar 8, 2013)
-
PR Newswire (Mar 7, 2013)
-
at CNBC.com (Mar 5, 2013)
-
at CNBC.com (Mar 5, 2013)
-
PR Newswire (Mar 5, 2013)
VVUS vs. ETF Alternatives
Company Description
VIVUS, Inc. is a biopharmaceutical company, incorporated in 1991, dedicated to the development and commercialization of therapeutic products for large underserved markets. Our investigational drugs currently under development could serve the obesity, diabetes and sexual health markets. Our... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 12:45 PM Vivus (VVUS -3.3%) slips today after pricing its $220M private placement of convertible senior unsecured notes due May 1, 2020. The notes will bear interest at a fixed annual rate of 4.50%, payable semiannually in arrears on May 1 and November 1 of each year, beginning on November 1, 2013. The net proceeds from the offering are expected to be approximately $213M. Comment! [Healthcare, On the Move]
- Wednesday, May 15, 2:06 PM Vivus (VVUS -3%) slips today after earlier announcing an aggregate $200M offering of convertible senior unsecured notes due May 1, 2020. It also intends to grant the initial purchasers a 30-day option to purchase up to an additional $30M. The company plans to use a portion of the net proceeds to pay the cost of a capped call transaction, and the remainder for continued development and commercialization of its products. 2 Comments [Healthcare, On the Move]
- Tuesday, May 14, 1:50 PM Vivus (VVUS +1.9%) continues to trade higher this week on hopes the company may partner with Big Pharma to expand access to the obesity drug Qsymia (I, II). Nevertheless, some, like Lazard's Joshua Schimmer, say the reality is that demand for the drug has so far proven tepid and VVUS "needs to find commercial success … or significantly reduce costs in order to slow the current cash outflow" — operating expenses rose 208% Y/Y in Q1. Lazard downgrades the shares to Neutral from Buy. Comment! [Healthcare, On the Move]
- Monday, May 13, 8:06 AM Vivus (VVUS) rises 2.6% premarket after sending a "business update" letter to shareholders outlining its progress on expanding access to its obesity drug Qsymia. The company reiterates some of the points made on the CC saying it is in discussions with Big Pharma regarding increasing the product's reach and notes the drug will be available at certified pharmacies by mid-July. Ultimately, VVUS says that with a combination of expanded access and reimbursement, Qsymia can be "a top-selling drug." (PR) 3 Comments [Healthcare, On the Move]
- Wednesday, May 8, 1:09 PM Vivus (VVUS +8.2%) pops despite posting a Q1 miss as sales of its weight-loss drug Qsymia came in lighter than analysts' expectations. The company wrote off $5.77M due to expired inventory, making it glaringly apparent that Qsymia's launch isn't going as planned. However, in its call, CEO Leland Wilson commented that the company is beginning discussions with large pharmaceutical companies in order to "significantly expand commercialization efforts." Wilson says VVUS has a target of mid-July to bring Qsymia into retail pharmacies. Read more on its earnings call here: Earnings Call Transcript. Comment! [Healthcare, Earnings, On the Move]
-
Wednesday, May 8, 9:17 AM
Premarket gainers: ALXA +51%. PSE +19%. LEDR +16%. NBG +11%. WFM +8%. EA +6%. PRTS +6%. SFUN +6%. CTSH +5%.
Losers: FIO -22%. VCLK -19%. OCLR -19%. AXLL -9%. CIE -7%. CHRW -7%. SODA -6%. DDD -6%. SYMC -5%. Z -5%. VVUS -5%. Comment! [On the Move] - Wednesday, May 8, 7:39 AM Vivus (VVUS): Q1 EPS of -$0.53 misses by $0.01. Revenue of $4.11M misses by $1.11M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, May 8, 12:05 AM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
- Tuesday, May 7, 5:30 PM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
- Tuesday, April 30, 11:21 AM Vivus (VVUS +2.2%) says that Qsymia has been added to Medco's national formulary in a tier-3 position with a prior authorization. According to Leerink Swann, the deal essentially converts Qsymia reimbursement from the non-covered to the covered position, and is potentially more important than the previous deal VVUS inked with Express Scripts. 1 Comment [Healthcare, On the Move]
- Friday, April 26, 11:12 AM Medivation (MDVN +0.6%) and Astellas Pharma (ALPMF.PK) say the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the oral androgen receptor inhibitor XTANDI (approved in the U.S.) for adult men with progressed metastatic castration-resistant prostate cancer. Other CHMP news: Pfizer's (PFE -1.1%) arthritis pill Xeljanz is rejected (appeal to come), Roche (RHHBY.OB +0.2%) and Curis' (CRIS +4.5%) Erivedge for basal cell carcinoma gets a recommendation, and Vivus' (VVUS +3.7%) ED drug Spedra gets a positive review. (See also: AVNR and CELG get thumbs up from EU regulators) 1 Comment [Healthcare, On the Move]
- Friday, April 19, 8:24 AM Vivus (VVUS) rises 5.4% premarket after saying in an 8K that sales of Qsymia rose 29% in March. The company now reports Qsymia shipments by the calendar month: January 16,733; February 18,417; March 23,812. Comment! [Healthcare, On the Move]
- Tuesday, April 16, 2:41 PM Vivus (VVUS +5%) spikes as the FDA approves its amendment and modification to the Risk Evaluation and Mitigation Strategy for Qsymia. The amendment, which was submitted last October, allows Qsymia to be dispensed through certified retail pharmacies in addition to the existing network of certified mail-order pharmacies, which reduces the prescribing burden for physicians and waiting times for patients seeking to initiate therapy. 5 Comments [Healthcare, On the Move]
- Tuesday, April 9, 4:13 PM Shares of Vivus (VVUS +3.5%) finish solidly in the green today as investors continue to expect Risk Evaluation and Mitigations Strategy modification for Qsymia. Cowen specutlates that many shorts are covering positions ahead of the decision. As of the end of March, over 26M shares, or 26% of the float, was being held short. Comment! [Healthcare, On the Move]
- Thursday, March 28, 5:21 PM Bacteria that live in the gut change after gastric-bypass surgery and may aid in weight loss, according to a recent study. Gastric surgery helps people lose weight by shrinking the size of the stomach and making it tougher to absorb calories, now scientists think it may also adjust gastrointestinal bacteria, contributing to weight loss and raising the possibility for less-drastic obesity treatment. 7 Comments [Healthcare]
- Wednesday, March 27, 10:46 AM Leerink Swann maintains Outperform on Vivus (VVUS -1.4%), price target $19-20. Management is making the right move to push out financing risk, says analyst Marko Kozul, who also notes that the "non-dilutive deal … helps mitigate previous higher than- anticipated spending on building the obesity market." (See: VVUS avoids dilution) Comment! [Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
wheelz23: if the market makers want to keep a stock price down...that's what happens -
phemale60: That's awful. I wanted to buy more at $10- was nearly there when shot back up. Don't like buying more at this price even tho prospects good.
-
- View all 0 replies
-
Day Trader001
$VVUS momentum rising on good news even though First Manhattan Co. that holds 9.1% of Vivus outstanding stock, - View all 2 replies
-
Day Trader001: said last week that the company's entry into retail pharmacies was necessary but not sufficient for Qsymia's success!
-
Day Trader001: This could mean $ARNA will also be on shelves very soon without the shareholder negativity.
-
Ryan Mallory
Fuinhaz Setups for April 17 2013 | $ARMH $ASML $ENDP $VVUS | SharePlanner http://bit.ly/12mdW8S - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
wheelz23: if the market makers want to keep a stock price down...that's what happens
-
phemale60: That's awful. I wanted to buy more at $10- was nearly there when shot back up. Don't like buying more at this price even tho prospects good.
-
Day Trader001
$VVUS momentum rising on good news even though First Manhattan Co. that holds 9.1% of Vivus outstanding stock, - View all 2 replies
-
Day Trader001: said last week that the company's entry into retail pharmacies was necessary but not sufficient for Qsymia's success!
-
Day Trader001: This could mean $ARNA will also be on shelves very soon without the shareholder negativity.
-
- View all 4 replies
-
-
-
Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it. - View all 3 replies
-
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
-
-
- View all 9 replies
-
phemale60: I had it since 2009 but was on a cruise when FDA approved, so held when at $31 - should've sold, went down so fast; sold at fraction.
-
phemale60: Now have at $13- been buying on dips near $10- but in red. Not for long tho. Need to be approved for retail pharmacies, then off it will go
-
- View all 2 replies
-
-
-
- View all 19 replies
-
-
-
- View all 3 replies
-
Day Trader001: The pattern formed over 29 days which is roughly the period of time in which the target price range may be achieved.
-
Day Trader001: This would be a hard drop if the chart pattern holds! "Back to the Raspberry Ultra Drops"
-
- View all 4 replies
-
FortSumter: Anybody tuning in to the Biggest Loser last night could easily see the products potential. Haha. -
-
- View all 7 replies
-
-
-
- View all 2 replies
-
-
phemale60: realornot: your day will come -- again -- always does. I think we're both in on the ground floor of something big (no pun intended)!
-
Michael Bryant
Novo Nordisk ($NVO) "is testing higher dosages [of its drugs] for use in obesity." Bad news for $ARNA & $VVUS http://bit.ly/VLBRb5 - View all 9 replies
-
-
Chemist357: To take a pill or inject yourself...I think Novo nordisk would have a long way to go. Only purpose extend patent life...
-
- View all 2 replies
-
Weight Issue: Analysts at Bloomberg Industries noted that Qsymia prescriptions gained 46% week-over-week, citing data from Symphony Health Solutions. -
-
- View all 47 replies
-
phemale60: Kept interest rates low for 4 years-can't be all bad. During extraordinary times must take extraordinary actions. Going to be late for work!
-
-
Vash Patel
Only investment I ever made based completely on emotion? $VVUS at $25 a few months ago. Needless to say emotional investments are a bad idea - View all 5 replies
-
phemale60: I had hoped to buy more at $10 --average down. May have that chance if fall off fiscal cliff end of year, or market reacts sooner.
-